About
LicensingBioLink WeeklyJob BoardNewsContact Us
Princeton, NJ — US-China Biopharma

Catalyzing US‑China
Biotech & Pharma
Partnerships

BioRich International connects leading pharmaceutical companies and biotech innovators across the US-China corridor — facilitating licensing deals, capital connections, and R&D collaboration.

Explore Our ServicesRead BioLink Weekly
0+
Chinese Clients
0+
Projects
0+
MNC Connections
0+
Years of Experience
Our Services

Comprehensive Support Across
the Deal Lifecycle

Licensing Deals

Out-licensing & in-licensing facilitation between Chinese biotechs and global pharma. 250+ clients, 400+ projects.

Learn more

Capital & Talent

We connect biopharma companies with pre-screened US venture capital and provide executive and scientific recruitment support — drawing on one of the most extensive personal networks in US-China biopharma to place the right people at the right time.

Learn more

CRO/CDMO Matching

Selecting the right contract research or manufacturing partner is one of the highest-stakes decisions in drug development. We leverage deep relationships across the China CRO/CDMO landscape — and beyond — to match clients with partners whose capabilities align with their program requirements.

Learn more

Market Research

Understanding the China biopharma market requires specialized knowledge that is difficult to source externally. Our proprietary market reports, combined with BioLink Weekly, provide the depth and currency needed to make confident strategic decisions.

Learn more
About BioRich

A Trusted Partner at the
Intersection of East and West

Founded by John Xu, MD, MBA, MS — with over 30 years of experience at Bristol Myers Squibb, Wyeth, WuXi AppTec, and CrownBio — BioRich International operates at the nexus of US and Chinese biopharma. We bridge the information, relationship, and cultural gaps that prevent high-potential deals from closing.

Our network encompasses 250+ Chinese biotech clients, direct relationships with BD&L leadership at 25+ multinational corporations, and active engagement with more than 10 US venture capital firms.

Meet our leadership
"

The biggest obstacle to deal-making is not interest or capital — it is information asymmetry. BioLink Weekly exists to close that gap.

John Xu, MD, MBA, MS

Founder & President, BioRich International

BioLink Weekly

Intelligence for US-China Biopharma Dealmakers

View all issues →
Issue 7May 24, 2026

PROTACs Enter Commercial Licensing; Gilead Closes $5B Tubulis; Lilly Makes Its 7th Acquisition of 2026

Rigel takes global rights to Veppanu — the first FDA-approved PROTAC — in an $85M near-term, $445M total deal that anchors the protein-degrader valuation template. Gilead's Tubulis acquisition closes at $5B (its first dedicated ADC buy of 2026), and Eli Lilly picks up Engage Biologics' non-viral DNA delivery platform — its seventh acquisition of the year.

Read issue
Issue 6May 16, 2026

BMS–Hengrui $15.2B Anchors a Three-Week Deal Wave; Lilly and Novo Reshape the Global Top 10

Seven major transactions in 21 days — BMS–Hengrui, Angelini–Catalyst, UCB–Candid, Merck–Terns, AbbVie–Kestrel, Rigel–VEPPANU, and GSK–Sino — against a Q1 reshuffle that put Eli Lilly at #1 and Novo Nordisk in the top five for the first time.

Read issue
Issue 5April 26, 2026

AI Moves From Pilot to Production as Q1 Deal Wave Continues

AI has shifted from experimental capability to operational infrastructure inside large pharma — Insilico–Sanofi, Recursion–NVIDIA, Anthropic–Coefficient Bio, and OpenFold3 set the tone, while ADC, radiopharma, and China-out-licensing activity continues to anchor the deal book.

Read issue

Ready to Explore a Partnership?

Whether you are seeking a licensing partner, an R&D collaborator, or strategic intelligence on the China market, we are ready to help.

Get in Touch